Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, scheduled for June 30, 2025, will feature a presentation by CEO and Chairman Robert Bitterman, who will provide an update on the company's proprietary INTASYL® siRNA technology. The presentation will include progress reports on the ongoing clinical trial of the lead compound PH-762, which is being developed for the treatment of skin cancers. Positive interim safety and efficacy results have already been reported from the Phase 1b dose escalation clinical trial of PH-762. The presentation and live Q&A session can be accessed via the Renmark Financial Communications Inc. website, with a replay available post-event.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。